October 2019
Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is currently conducting more than 120 research studies, including clinical trials of targeted therapies and novel immunotherapy approaches.
New studies offer novel therapies for
patients with GI cancers
Providence Cancer Institute offers several studies of targeted therapies, immunotherapies and combination therapies for patients with GI cancers, including cancers of the biliary tract:

  • Durvalumab or placebo in combination with gemcitabine/cisplatin in patients with first-line advanced biliary tract cancer (TOPAZ-1)
  • A study to evaluate the efficacy and safety of pemigatinib versus chemotherapy in unresectable or metastatic cholangiocarcinoma (FIGHT-302)
All current open studies:
Find additional studies for many types of cancer in Multiple Tumor Types .
New studies are posted frequently - please check our  website  for a complete list of our current studies. For more information, call 503-215-2614.